98K
Downloads
69
Episodes
Written by expert consultants and clinical scientists currently practising in the UK, the BSH Guidelines provide up-to-date evidence-based guidance on the diagnosis and treatment of haematological diseases. Self accreditation Listen to two podcasts and earn one CPD point via self-accreditation Join our Guidelines Newsletter to be notified when new guidelines/good practice papers are published by going into your members account under MyBSH. Non members can email bshguidelines@b-s-h.org.uk to sign up for updates.
Episodes
5 days ago
5 days ago
In this episode, Dr Sridhar Chaganti shares with us the highlights in large B-cell lymphoma from BSH 2025, including real-world experience in the use of bispecific antibodies and the recent NICE approval of Lisocel as second line treatment.
Dr Chaganti is a Consultant Haemato-oncologist at the University Hospital in Birmingham, with an interest in lymphomas, ALL, stem cell transplantation and immune effector cell therapies including CART cell therapy. He is the chair of the high-grade lymphoma study group and co-chairs the national CAR-T panel.
No comments yet. Be the first to say something!